Isordil: Effective Angina Prevention and Relief
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.86 | $51.60 (0%) | 🛒 Add to cart |
| 90 | $0.64 | $77.40 $57.62 (26%) | 🛒 Add to cart |
| 120 | $0.52 | $103.20 $61.92 (40%) | 🛒 Add to cart |
| 180 | $0.43 | $154.80 $77.40 (50%) | 🛒 Add to cart |
| 270 | $0.39 | $232.20 $104.06 (55%) | 🛒 Add to cart |
| 360 | $0.36
Best per pill | $309.60 $129.86 (58%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.73 | $43.86 (0%) | 🛒 Add to cart |
| 90 | $0.60 | $65.79 $54.18 (18%) | 🛒 Add to cart |
| 120 | $0.48 | $87.72 $57.62 (34%) | 🛒 Add to cart |
| 180 | $0.36 | $131.58 $64.50 (51%) | 🛒 Add to cart |
| 270 | $0.32 | $197.37 $87.72 (56%) | 🛒 Add to cart |
| 360 | $0.30
Best per pill | $263.16 $108.36 (59%) | 🛒 Add to cart |
Isordil (isosorbide dinitrate) is a potent vasodilator belonging to the organic nitrate class, specifically formulated for the prophylaxis and treatment of angina pectoris attacks. It functions primarily by reducing cardiac preload and afterload through venous and arterial dilation, thereby decreasing myocardial oxygen demand. This medication is a cornerstone in the management of coronary artery disease, offering both acute symptomatic relief and long-term preventive benefits. Its well-established efficacy profile makes it a first-line option in numerous clinical guidelines for cardiovascular care.
Features
- Active ingredient: Isosorbide dinitrate
- Available formulations: Sublingual tablets, chewable tablets, oral tablets, extended-release capsules
- Standard strengths: 5 mg, 10 mg, 20 mg, 30 mg, 40 mg
- Mechanism of action: Nitric oxide donor causing venous and arterial vasodilation
- Onset of action: Sublingual: 2–5 minutes; Oral: 20–60 minutes
- Duration of effect: Sublingual: 1–2 hours; Oral: 4–6 hours; Extended-release: 8–12 hours
- Bioavailability: Approximately 25% due to significant first-pass metabolism
- Half-life: 1–4 hours (parent compound); 2–5 hours (active metabolites)
Benefits
- Rapid relief of acute angina attacks when administered sublingually
- Significant reduction in frequency and severity of angina episodes with regular prophylactic use
- Decreased myocardial oxygen demand through reduced preload and afterload
- Improved exercise tolerance and functional capacity in patients with stable angina
- Flexible dosing regimens adaptable to individual patient needs and response patterns
- Well-documented safety profile with extensive clinical experience spanning decades
Common use
Isordil is primarily indicated for the prevention and treatment of angina pectoris resulting from coronary artery disease. It is employed in both acute settings for immediate symptom relief and as chronic therapy for angina prophylaxis. The sublingual formulation is particularly valuable for aborting ongoing angina attacks, while oral formulations are used for maintenance therapy. Additionally, Isordil may be used off-label in the management of congestive heart failure, specifically for afterload reduction in acute decompensated cases, though this application requires careful hemodynamic monitoring.
Dosage and direction
Dosage must be individualized based on therapeutic response and tolerance. For acute angina relief: place one sublingual tablet (5 mg) under the tongue or in the buccal pouch at the onset of an attack; may repeat every 5-10 minutes for up to three doses within 15-30 minutes. For prophylaxis: initial oral dose is typically 5-20 mg two to three times daily, with at least a 14-hour nitrate-free interval to prevent tolerance development. Extended-release formulations are usually administered as 40 mg once or twice daily. Patients should be instructed to sit down when taking the medication to minimize orthostatic hypotension risk. Tablets should not be crushed or chewed (except designated chewable formulations).
Precautions
Patients should be monitored for signs of hypotension, particularly during initial dose titration. Tolerance to antianginal effects and hemodynamic effects may develop with continuous exposure; employing a nitrate-free interval of 10-14 hours daily is essential to maintain efficacy. Abrupt discontinuation may precipitate rebound angina. Use with caution in patients with hypovolemia, hypertrophic cardiomyopathy, or constrictive pericarditis. Cerebral hemodynamics may be affected, requiring caution in patients with increased intracranial pressure. Regular assessment of angina frequency and exercise tolerance is recommended to evaluate therapeutic response.
Contraindications
Isordil is contraindicated in patients with known hypersensitivity to organic nitrates or any component of the formulation. Concomitant use with phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) is absolutely contraindicated due to risk of profound hypotension. Additional contraindications include severe anemia, increased intracranial pressure, and circulatory failure associated with marked hypotension (shock). Should not be used in patients with acute myocardial infarction with low filling pressures or in those with inadequate cerebral circulation.
Possible side effects
The most common adverse effects are headache (which often diminishes with continued therapy) and hypotension, manifesting as dizziness, lightheadedness, or syncope. Cutaneous vasodilation with flushing may occur. Less frequently reported effects include tachycardia, paradoxical bradycardia, nausea, vomiting, and weakness. Rare but serious adverse effects include methemoglobinemia (particularly with overdose), increased intraocular pressure, and dermatitis with prolonged contact. Sublingual administration may cause local burning or tingling sensations.
Drug interaction
Concomitant use with phosphodiesterase-5 inhibitors can cause severe hypotension and is absolutely contraindicated. Additive hypotensive effects may occur with other vasodilators, antihypertensives, calcium channel blockers, beta-blockers, alcohol, and tricyclic antidepressants. Aspirin may increase nitrate serum concentrations. Heparin’s anticoagulant effect may be reduced. Ergot alkaloids may antagonize the vasodilatory effects. Sympathomimetics may reduce the antianginal efficacy. Concurrent use with riociguat should be avoided due to additive hypotensive effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. For sublingual tablets used for acute attacks, this guidance does not apply as they are taken on an as-needed basis rather than a scheduled regimen.
Overdose
Symptoms of overdose primarily involve vasodilation and include severe hypotension, syncope, persistent throbbing headache, dizziness, palpitations, visual disturbances, nausea, vomiting, and diaphoresis. Methemoglobinemia may occur with massive overdose, manifesting as cyanosis, hypoxia, fatigue, and tachycardia. Treatment involves supportive measures including elevation of lower extremities, administration of intravenous fluids, and if necessary, vasopressors. Methylene blue may be required for methemoglobinemia. Hemodialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) in the original container. Protect from light, moisture, and heat. Keep sublingual tablets in their original glass container with cotton removed and tightly closed. Do not transfer to other containers. Do not store in bathroom areas where moisture levels may be high. Keep all medications out of reach of children and pets. Discard any medication that has changed color or shows signs of deterioration.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual therapeutic decisions should be made by qualified healthcare professionals based on comprehensive patient assessment. Always follow the prescribing information provided with the medication. Patients should not alter their dosage or discontinue medication without consulting their physician. While every effort has been made to ensure accuracy, medical knowledge evolves and this information may not reflect the most current research or recommendations.
Reviews
Clinical studies consistently demonstrate Isordil’s efficacy in reducing angina frequency by 50-70% and improving exercise tolerance in approximately 60-80% of patients. The sublingual formulation provides rapid relief within 2-5 minutes in most cases. Long-term studies show maintained efficacy when proper nitrate-free intervals are observed. Tolerance development remains a consideration with continuous dosing but is effectively managed through appropriate dosing schedules. The safety profile is generally favorable, with headache being the most frequently reported adverse effect, though this often diminishes with continued therapy. Overall, Isordil remains a well-established and reliable option in angina management.